Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipoic Acid for Neuroprotection in SPMS
NCT01188811Phase 3Completed
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2010
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Lipoic Acid with Placebo (2 arms). Primary endpoint: Percent Change in Brain Volume at 2 years. Started Oct 2010; status: completed.
02
Drugs
alpha-lipoic acid
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT01188811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01188811.